MDSpire - Summary
Feature

Diagnosis: Delayed – The Case for Faster Companion Diagnostic Delivery

From approvals and reimbursement to in-house testing and tissue stewardship - Jane Li discusses the barriers to precision diagnostics, and the route through them

Share

Companion diagnostics can enhance targeted therapy effectiveness, yet their integration into routine patient care remains inconsistent. Jane Li from Thermo Fisher Scientific highlights the challenges of biomarker adoption, including extensive evidence requirements and operational integration in community hospitals. Reimbursement issues further complicate matters, requiring alignment among stakeholders. The disparity in adoption between academic centers and community hospitals underscores the need for education and reinforcement of the value of precision medicine to ensure equitable patient access to effective treatments.

Original Source(s)

Diagnosis: Delayed – The Case for Faster Companion Diagnostic Delivery

  • by Helen Bristow

  • April 2, 2026

Related Content

Financial Hardship and Late-Stage Cancer Diagnosis

In a study reported in the Journal of Clinical Oncology, Khor et al found that prediagnosis financial hardship was associated with a diagnosis of cancer at later stages, particularly for cancers with ...

A New Route to Lymphoma Diagnosis

Liquid biopsy detects EBV-positive Burkitt’s cases with high specificity

  • April 2, 2026

  • 3 min
The Scent of an Ancient Mummy

Airborne chemical fingerprints uncover evolving preservation recipes and offer a non-destructive way to study ancient remains

  • April 2, 2026

  • 2 min